Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 701 Phase 3 in Late-Onset Pompe Disease Previously Treated With rhGAA
jRCT2080222781Phase 3
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Mar 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reveglucosidase alfa in Pompe disease, sponsored by BioMarin Pharmaceutical Inc.
02
Drugs
reveglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on jRCT2080222781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222781.